Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,848Revenue $M198Net Margin (%)-0.5Altman Z-Score11.0
Enterprise Value $M2,797EPS $-0.4Operating Margin %3.4Piotroski F-Score7
P/E(ttm)--Beneish M-Score-2.0Pre-tax Margin (%)-0.3Higher ROA y-yY
Price/Book17.910-y EBITDA Growth Rate %--Quick Ratio1.3Cash flow > EarningsY
Price/Sales13.35-y EBITDA Growth Rate %--Current Ratio1.6Lower Leverage y-yY
Price/Free Cash Flow651y-y EBITDA Growth Rate %--ROA % (ttm)-0.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-0.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M36.4ROIC % (ttm)6.9Gross Margin Increase y-yY

Gurus Latest Trades with PCRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PCRXMariko Gordon 2015-03-31 Reduce-0.12%$85.01 - $119.27
($101.46)
$ 78.16-23%Reduce 4.30%659,998
PCRXGeorge Soros 2015-03-31 Sold Out -0.084%$85.01 - $119.27
($101.46)
$ 78.16-23%Sold Out0
PCRXRon Baron 2015-03-31 Add0.01%$85.01 - $119.27
($101.46)
$ 78.16-23%Add 22.79%82,380
PCRXJoel Greenblatt 2015-03-31 Buy 0.01%$85.01 - $119.27
($101.46)
$ 78.16-23%New holding9,319
PCRXMariko Gordon 2014-12-31 Reduce-0.54%$86.02 - $107.8
($94.65)
$ 78.16-17%Reduce 15.33%689,628
PCRXGeorge Soros 2014-12-31 Buy 0.08%$86.02 - $107.8
($94.65)
$ 78.16-17%New holding87,000
PCRXJoel Greenblatt 2014-12-31 Sold Out -0.01%$86.02 - $107.8
($94.65)
$ 78.16-17%Sold Out0
PCRXKen Fisher 2014-12-31 Buy $86.02 - $107.8
($94.72)
$ 78.16-17%New holding4,800
PCRXMariko Gordon 2014-09-30 Reduce-1.21%$83.31 - $108.26
($97.65)
$ 78.16-20%Reduce 28.09%814,470
PCRXRon Baron 2014-09-30 Reduce-0.03%$83.31 - $108.26
($97.65)
$ 78.16-20%Reduce 59.75%62,139
PCRXJoel Greenblatt 2014-09-30 Reduce$83.31 - $108.26
($97.65)
$ 78.16-20%Reduce 26.78%6,946
PCRXMariko Gordon 2014-06-30 Reduce-0.66%$63.61 - $91.01
($75.89)
$ 78.163%Reduce 17.39%1,132,552
PCRXRon Baron 2014-06-30 Add0.05%$63.61 - $91.01
($75.89)
$ 78.163%Add 802.88%154,393
PCRXJoel Greenblatt 2014-06-30 Buy 0.01%$63.61 - $91.01
($75.89)
$ 78.163%New holding9,486
PCRXMariko Gordon 2014-03-31 Add0.19%$55.83 - $80.43
($67.63)
$ 78.1616%Add 5.13%1,371,042
PCRXRon Baron 2014-03-31 Add$55.83 - $80.43
($67.63)
$ 78.1616%Add 163.28%17,100
PCRXMariko Gordon 2013-12-31 Add2.08%$47.74 - $56.97
($52.53)
$ 78.1649%Add 203.52%1,304,190
PCRXRon Baron 2013-12-31 Buy $47.74 - $56.97
($52.53)
$ 78.1649%New holding6,495
PCRXMariko Gordon 2013-09-30 Add0.93%$30.01 - $47.47
($36.37)
$ 78.16115%Add 3812.66%429,688
PCRXMariko Gordon 2013-06-30 Buy 0.02%$25.84 - $30.26
($28.93)
$ 78.16170%New holding10,982
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PCRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STACK DAVID MPresident, CEO and Chairman 2015-04-15Sell25,000$90.5-13.64view
HASTINGS PAUL JDirector 2015-04-10Sell2,500$88-11.18view
Riker Lauren BullaroExecutive Director, Finance 2015-03-16Sell5,000$95.34-18.02view
PACE GARY WDirector 2015-03-13Buy1,000$93.83-16.7view
LONGENECKER JOHN P PHDDirector 2015-03-12Sell3,000$95.28-17.97view
Scibetta James SSVP, CFO 2015-02-06Sell15,000$111.22-29.72view
STACK DAVID MPresident, CEO and Chairman 2015-01-15Sell15,000$97.52-19.85view
HASTINGS PAUL JDirector 2015-01-12Sell2,500$94.06-16.9view
LONGENECKER JOHN P PHDDirector 2014-12-29Sell1,000$93.32-16.25view
WINGER DENNIS LDirector 2014-12-05Buy2,645$94.54-17.33view

Press Releases about PCRX :

    Quarterly/Annual Reports about PCRX:

    News about PCRX:

    Articles On GuruFocus.com
    Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
    SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Pacira Pharmace Nov 28 2014 
    Mariko Gordon's First Quarter Top Five May 15 2014 
    Baron Funds Comments on Pacira Pharmaceuticals Mar 05 2014 
    comment on PCRX Mar 15 2013 
    Weekly CFO Buys Highlight: PCRX, UGI, MIG, GLT, IOSP Feb 27 2011 
    Weekly CFO Buys Highlight: REFR, UGI, PCRX, NOIZ Feb 21 2011 
    Pacira Pharmaceuticals Inc. (PCRX) CFO James S Scibetta buys 5,000 Shares Feb 16 2011 
    Pacira Pharmaceuticals Inc. (PCRX) CEO David M Stack buys 5,000 Shares Feb 11 2011 

    More From Other Websites
    Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in June May 20 2015
    Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in June May 20 2015
    Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients... May 19 2015
    Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients... May 19 2015
    Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2015 Health Care... May 07 2015
    Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2015 Health Care... May 07 2015
    PACIRA PHARMACEUTICALS, INC. Financials May 06 2015
    10-Q for Pacira Pharmaceuticals, Inc. May 04 2015
    Pacira Down on Revenue Miss in Q1, Beat on Earnings - Analyst Blog May 04 2015
    Pacira Pharmaceuticals (PCRX): Moving Average Crossover Alert - Tale of the Tape Apr 30 2015
    Pacira Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET today Apr 30 2015
    PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 30 2015
    Q1 2015 Pacira Pharmaceuticals Inc Earnings Release - Before Market Open Apr 30 2015
    Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First... Apr 30 2015
    Pacira beats 1Q profit forecasts Apr 30 2015
    Pacira beats 1Q profit forecasts Apr 30 2015
    Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First... Apr 30 2015
    Lifshitz & Miller Law Firm Announces Investigation of AudioEye, Inc., Cellular Biomedicine Group... Apr 27 2015
    Pacira Down on Subpoena on Exparel Marketing Issues - Analyst Blog Apr 17 2015
    Pacira Pharmaceuticals (PCRX) Falls: Stock Goes Down 9.7% - Tale of the Tape Apr 17 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK